A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 2, 2001, Pages 125-132

  Posey, James A ^a   Khazaeli, M B ^a   DelGrosso, Alma ^a   Saleh, Mansoor N ^a   Chin, Yu Lin ^a   Huse, William ^b   LoBuglio, Albert F ^a  

^a University of Alabama at Birmingham   (United States)

^b Applied Molecular Evolution   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; HUMAN MONOCLONAL ANTIBODY ALPHA V BETA 3; MONOCLONAL ANTIBODY LM 609; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTIBODY;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HEADACHE; HUMAN; MALE; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BLOOD FLOW; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PILOT PROJECTS; RECEPTORS, VITRONECTIN;

EID: 0035706407     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801300189218     Document Type: Article

References (25)

1. Incipient angiogenesis
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Angiogenesis and cancer metastasis
4. Critical determinants of neoplastic angiogenesis
5. A cancer therapy resistant to resistance
6. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
7. v integrins
8. Adhesion Molecules Part I
9. 3 for angiogenesis science
10. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
11. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and on Willebrand factor
12. The role of alpha v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
13. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
14. Suppression of p53 activity and p21 sup WAF1/CIP1 expression by vascular cell integrin alpha v beta 3 during angiogenesis
15. 3
16. 3-specific humanized mAb
17. 2 fragments with Technetium-99mm
18. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
19. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
20. Human immune response to monoclonal antibodies
21. Vascular expression of the alpha(v) beta(3)-integrin in lung and other organs
22. 3 expression on tumor-associated vessels of human carcinomas
23. A pilot study of an angiogenesis inhibitor vitaxin in patients with advanced leiomyosarcomas (leios)
24. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis